Sarah Ramsden

Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison

Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new formulation of aripiprazole monohydrate intended for the treatment of schizophrenia or maintenance mono...

Heather Fitzgerald ;

Sarah Ramsden ;

01/19/2023

Prevention in Practice: Improving Communication on the Benefits of Treatments for Schizophrenia

Abstract: Antipsychotic treatment can help improve outcomes in schizophrenia by reducing the risk of relapse and psychiatric hospitalization, and increasing rates of remission and recover...

Sarah Ramsden ;

Murat Yilidirm ;

01/19/2023

Pharmacokinetic Profile of Multiple-Dose Aripiprazole 2-Month Ready-to-Use 960 mg Versus Aripiprazole Once-Monthly 400 mg in Adults With Schizophrenia or Bipolar I Disorder

Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, inten...

Matthew Harlin , MD, MS;

Sarah Ramsden ;

01/19/2023

Safety And Tolerability of Multiple-Dose Aripiprazole 2-Month Ready-to-Use 960 mg Versus Aripiprazole Once-Monthly 400 mg in Adults With Schizophrenia or Bipolar I Disorder

Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, inten...

Pedro Such , MD;

Sarah Ramsden ;

01/19/2023